AllSci News
Soligenix’s SGX945 recommended for EMA Orphan Drug Designation for Behçet’s disease
Soligenix, Inc., a Princeton, New Jersey–based late-stage biopharmaceutical company, revealed that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has…
WuXi XDC, Earendil Labs form ADC collaboration worth up to USD 885m
WuXi XDC Cayman Inc. (2268.HK), a Shanghai-based CRDMO specializing in bioconjugates, and US-based Earendil Labs, an AI-driven biotechnology company, have entered a…
Generate Biomedicines prices IPO at USD 400m, begins trading on Nasdaq
Generate Biomedicines, Inc. (Nasdaq: GENB), a clinical-stage generative biology company based in Somerville, Massachusetts, announced the pricing of its initial public offering.…
AtaiBeckley’s MDMA drug shows positive Phase IIa results in social anxiety disorder
New York-based AtaiBeckley (NASDAQ: ATAI) announced topline results from its exploratory Phase IIa trial evaluating EMP-01, an oral R-MDMA candidate, in adults…
BMS’s SystImmune bispecific ADC aces endpoints in Phase III for triple-negative breast cancer
US-based SystImmune and Bristol Myers Squibb announced positive interim topline results from a Phase III trial of izalontamab brengitecan (iza-bren), a bispecific…
Lilly’s oral GLP-1 orforglipron beats semaglutide in efficacy but not safety
Eli Lilly and Company announced detailed Phase III data from the ACHIEVE-3 trial evaluating its investigational oral GLP-1 receptor agonist orforglipron in…
SPARK NS allocates up to USD 18m to 9 academic projects in autism and Parkinson’s
SPARK NS, an independent nonprofit translational research organization headquartered in Menlo Park, California, has selected nine academic projects and principal investigators to…
Beam secures USD 500m financing as Pfizer licenses in vivo base editing candidate
Beam Therapeutics announced a USD 500 million strategic financing alongside Pfizer’s opt-in to an exclusive global license for a liver-targeted in vivo…
MacroGenics pauses enrollment in study for PD-1×CTLA-4 bispecific lorigerlimab after patient death
MacroGenics announced that the US FDA has placed a partial clinical hold on the Phase II LINNET study evaluating lorigerlimab, an investigational…
ARPA-H hands out USD 144m to tackle aging, universities and biotechs in support
The US Advanced Research Projects Agency for Health (ARPA-H) announced the selection of seven research teams under its PROactive Solutions for Prolonging…
Novo Nordisk licenses Vivtex’s oral biologics delivery platform in USD 2.1b deal
Novo Nordisk A/S entered into a global technology licensing agreement with US-based oral biologics delivery company Vivtex Corporation that will see Novo…
GSK closing in on USD 950m purchase of 35Pharma for pulmonary hypertension drug
UK giant GSK plc revealed the signing of an agreement to acquire privately held Canadian biotech 35Pharma for USD 950 million in…
Accent Therapeutics halts study of first-in-class DHX9 molecule after safety findings
US-based Accent Therapeutics has terminated the sole clinical trial for ATX-559, an oral inhibitor of the RNA helicase DHX9, after enrolling 17…
BreezeBio raises USD 60m Series B for mRNA-based nanoparticle pipeline
San Francisco-based BreezeBio Inc., formerly known as GenEdit, a biotechnology company developing targeted genetic medicines using nanoparticle-based delivery systems, closed a Series…
Rare derma disease firm Palvella targets USD 150m in secondary offering
US-based Palvella Therapeutics (Nasdaq: PVLA) announced the commencement of an underwritten public offering of USD 150 million of shares of its common…
The AllSci Brief
Free, systematic R&D and deal news. Daily.